健康新聞
All coverage
- ACLIDINIUM 相關新聞
- ANDEXANET ALFA 相關新聞
- CALCIUM 相關新聞
- CENTELLA ASIATICA 相關新聞
- CISATRACURIUM 相關新聞
- ECHINACEA 相關新聞
- GINKGO BILOBA 相關新聞
- GLYCOPYRRONIUM 相關新聞
- ISAVUCONAZONIUM 相關新聞
- LITHIUM 相關新聞
- MAGNESIUM 相關新聞
- MIVACURIUM 相關新聞
- SELENIUM 相關新聞
- STRONTIUM 相關新聞
- TIOTROPIUM 相關新聞
- UMECLIDINIUM 相關新聞
About the Developer
This platform is developed and operated by 藥提醒科技有限公司 (yao.care, company registration number 83620786, 12F, No. 220, Sec. 2, Taiwan Blvd., West Dist., Taichung City, Taiwan).
CHTxGNN is the Switzerland site of the company's "TxGNN Drug Repurposing" product line.
The same system is deployed across 30 countries and regions, each named {CC}TxGNN
(JpTxGNN, UsTxGNN, DETxGNN, and so on) at {cc}txgnn.yao.care.
Product overview: https://www.yao.care/medical/txgnn/.
The TxGNN model itself was developed by the Zitnik Lab at Harvard Medical School and published in Nature Medicine. This platform is the production system 藥提醒科技有限公司 built on top of that model, covering national drug-registration data integration, dual knowledge-graph and deep-learning prediction, PubMed / ClinicalTrials evidence grading, and SMART on FHIR electronic health record integration.
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)